Chronic activation of AMP-activated protein kinase leads to early-onset polycystic kidney phenotype.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
29 10 2021
Historique:
received: 19 08 2021
revised: 27 09 2021
accepted: 07 10 2021
pubmed: 9 10 2021
medline: 15 12 2021
entrez: 8 10 2021
Statut: ppublish

Résumé

AMP-activated protein kinase (AMPK) plays a key role in the cellular response to low energy stress and has emerged as an attractive therapeutic target for tackling metabolic diseases. Whilst significant progress has been made regarding the physiological role of AMPK, its function in the kidney remains only partially understood. We use a mouse model expressing a constitutively active mutant of AMPK to investigate the effect of AMPK activation on kidney function in vivo. Kidney morphology and changes in gene and protein expression were monitored and serum and urine markers were measured to assess kidney function in vivo. Global AMPK activation resulted in an early-onset polycystic kidney phenotype, featuring collecting duct cysts and compromised renal function in adult mice. Mechanistically, the cystic kidneys had increased cAMP levels and ERK activation, increased hexokinase I (Hk I) expression, glycogen accumulation and altered expression of proteins associated with autophagy. Kidney tubule-specific activation of AMPK also resulted in a polycystic phenotype, demonstrating that renal tubular AMPK activation caused the cystogenesis. Importantly, human autosomal dominant polycystic kidney disease (ADPKD) kidney sections revealed similar protein localisation patterns to that observed in the murine cystic kidneys. Our findings show that early-onset chronic AMPK activation leads to a polycystic kidney phenotype, suggesting dysregulated AMPK signalling is a contributing factor in cystogenesis.

Identifiants

pubmed: 34622923
pii: 229892
doi: 10.1042/CS20210821
doi:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
TFEB protein, human 0
Cyclic AMP E0399OZS9N
HK1 protein, human EC 2.7.1.1
Hexokinase EC 2.7.1.1
Extracellular Signal-Regulated MAP Kinases EC 2.7.11.24
AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2393-2408

Subventions

Organisme : Medical Research Council
ID : MC_U120027537
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/62/31288
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-A654-5QB10
Pays : United Kingdom

Informations de copyright

© 2021 The Author(s).

Auteurs

Laura Wilson (L)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.

Alice E Pollard (AE)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.
Structure Biophysics and Fragments, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, U.K.

Lucy Penfold (L)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.

Phillip J Muckett (PJ)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.

Chad Whilding (C)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.

Mohammad Bohlooly-Y (M)

Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Patricia Wilson (P)

Centre for Nephrology, UCL Department of Renal Medicine, Royal Free Campus, London NW3 2PF, U.K.

David Carling (D)

MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, Imperial College London, W12 0NN U.K.
Institute of Clinical Sciences, Imperial College London, Hammersmith Hospital, London W12 0NN, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH